H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cognition Therapeutics (CGTX) to $3 from $5 and keeps a Buy rating on the shares. The firm cites the anticipated equity dilution later this year to extend the company’s operational runway for the target cut. Zervimesine appears applicable across multiple fronts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics presents preclinical data on zervimesine at ARVO
- Cognition Therapeutics Reports Q1 2025 Financials and Progress
- Cognition Therapeutics reports results from Phase 2 COG2201 trial
- Cognition Therapeutics Announces Positive Phase 2 Trial Results
- Cognition Therapeutics reports Q1 EPS (14c), consensus (12c)